YmAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. Our lead antibody programs target GD2 and B7-H3. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/26/17 | $50,000,000 |
HBM Healthcare Investments | undisclosed |
